NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 175 filers reported holding NEVRO CORP in Q4 2022. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $86,090 | -23.1% | 2,174 | -9.7% | 0.00% | -42.9% |
Q3 2022 | $112,000 | -23.8% | 2,408 | -28.2% | 0.01% | 0.0% |
Q2 2022 | $147,000 | +4.3% | 3,354 | +72.4% | 0.01% | +16.7% |
Q1 2022 | $141,000 | -18.0% | 1,945 | -8.2% | 0.01% | 0.0% |
Q4 2021 | $172,000 | -61.8% | 2,118 | -45.2% | 0.01% | -57.1% |
Q3 2021 | $450,000 | -38.4% | 3,864 | -12.4% | 0.01% | -17.6% |
Q2 2021 | $731,000 | +18.9% | 4,412 | 0.0% | 0.02% | +13.3% |
Q1 2021 | $615,000 | -33.2% | 4,412 | -17.0% | 0.02% | -25.0% |
Q4 2020 | $921,000 | -20.3% | 5,318 | -35.9% | 0.02% | -20.0% |
Q3 2020 | $1,155,000 | +259.8% | 8,295 | +47.5% | 0.02% | +257.1% |
Q3 2018 | $321,000 | -19.8% | 5,625 | +12.4% | 0.01% | -22.2% |
Q2 2018 | $400,000 | -7.8% | 5,005 | 0.0% | 0.01% | -10.0% |
Q1 2018 | $434,000 | +25.4% | 5,005 | 0.0% | 0.01% | +25.0% |
Q4 2017 | $346,000 | -57.9% | 5,005 | -44.6% | 0.01% | -57.9% |
Q3 2017 | $821,000 | +50.1% | 9,029 | +22.8% | 0.02% | +58.3% |
Q2 2017 | $547,000 | +10.3% | 7,352 | +54.6% | 0.01% | +9.1% |
Q3 2016 | $496,000 | – | 4,754 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |